Skip to main content
SpringerLink
Log in

B Psoriatic Arthritis

  • Chapter
Psoriasis and Psoriatic Arthritis

  • 1335 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Moreland LW, Schiff MD, Baumgartner SW, et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130(6): 478–486.

    PubMed  CAS  Google Scholar 

  2. Weinblatt ME, Kremer JM, Bankhurst AD, et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4): 253–259.

    Article  PubMed  CAS  Google Scholar 

  3. Maini R, Breedveld FC, Kalden JR, et al. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monocolonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563.

    Article  PubMed  CAS  Google Scholar 

  4. Maini R, St. Clair EW, Breedveld F, et al. (1999) Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 354: 1932–1939.

    Article  PubMed  CAS  Google Scholar 

  5. Lipsky PE, van der Heijde DM, St. Clair EW, et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343: 1594–1602.

    Article  PubMed  CAS  Google Scholar 

  6. Bathon JM, Martin RW, Fleischmann RM, et al. (2000) A comparison of etancercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22): 1586–1593.

    Article  PubMed  CAS  Google Scholar 

  7. Genovese MD, Bathon JM, Martin RW, et al. (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis; two-year radiographic and clinical outcomes. Arthritis Rheum 46(6): 1443–1450.

    Article  PubMed  CAS  Google Scholar 

  8. Ritchlin C, Haas-Smith SA, Hicks D, et al. (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25(8): 1544–1552.

    PubMed  CAS  Google Scholar 

  9. Danning CL, Illei GG, Hitchon C, et al. (2000) Macrophage-derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43: 1244–1256.

    Article  PubMed  CAS  Google Scholar 

  10. Mizutani H, Ohmoto Y, Mizutani T, et al. (1997) Role of increased production of monocytes TNF-α, IL-1β and Il-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 14: 145–153.

    Article  PubMed  CAS  Google Scholar 

  11. Partsch F, Steiner G, Leeb BF, et al. (1997) Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24: 518–523.

    PubMed  CAS  Google Scholar 

  12. Bonifati C, Ameglio F (1999) Cytokines in psoriasis. Int J Dermatol 101: 783–794.

    Google Scholar 

  13. Ettehadi P, Greaves NW, Wallach D, et al. (1994) Elevated tumor necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions. Clin Exp Immunol 96: 146–151.

    PubMed  CAS  Google Scholar 

  14. Mussi A, Bonifati C, Carucci M, et al. (1997) Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 11: 115–118.

    PubMed  CAS  Google Scholar 

  15. Chodorowska G (1998) Plasma Concentrations of IFN-γ and TNF-α in psoriatic patients before an after local treatment with dithranol ointment. J Eur Acad Dermatol Venerol 10: 147–151

    Article  CAS  Google Scholar 

  16. Wakefield PE, James WD, Samlaska CP (1991) Tumor necrosis factor. J Am Acad Dermatol 24: 675–685.

    Article  PubMed  CAS  Google Scholar 

  17. Feldmann M, Brennan FM, Maini RN (1995) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397–440.

    Article  Google Scholar 

  18. Terajima S, Higaki M, Igarashi Y, et al. (1998) An important role of tumor necrosis factor-α in the induction of adhesion molecules in psoriasis. Arch Dermatol Res 290: 246–252.

    Article  PubMed  CAS  Google Scholar 

  19. Barnes PJ, Karin M (1997) Nuclear factor-kappaB A pivotal transcription factor in chronic inflammatory diseases. NEJM 336: 1066–1072.

    Article  PubMed  CAS  Google Scholar 

  20. Saklatvala J (1986) Tumor necrosis factor alpha stimulates resoption and inhibits synthesis of proteoglycan in cartilage. Nature 322: 547–549.

    Article  PubMed  CAS  Google Scholar 

  21. Bertolini DR, Nedwin GE, Bringman TS, et al. (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 319: 516–518.

    Article  PubMed  CAS  Google Scholar 

  22. Shinmei M, Masuda K, Kikuchi T, Shimomura Y (1989) The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol 6(suppl 18): 32–34.

    Google Scholar 

  23. Dayer JM, Beutler B, Cerami A (1985) Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162: 2163–2168.

    Article  PubMed  CAS  Google Scholar 

  24. Ritchlin C (2003) Mechanisims of TNF-alpha and RANKL mediated osteoclastogenesis and bone resoption in psoriatic arthritis. Journal of Clin Invest 111(6): 821–831.

    CAS  Google Scholar 

  25. Nickoloff BJ (1999) The immunologic and genetic basis of psoriasis. Arch Dermatol 135: 1104–1110.

    Article  PubMed  CAS  Google Scholar 

  26. Mease PJ. Psoriatic Arthritis/Psoriasis. ch.32 in Smolen JS, Lipsky PE (eds.) Targeted Therapies in Rheumatology. Martin Dunitz, London, 2003.

    Google Scholar 

  27. Mease PJ (2003) Current treatment of psoriatic arthritis. Rheum Dis Clin N Am 29: 495–511.

    Article  Google Scholar 

  28. Mease PJ (2003) Recent advances in the treatment of psoriatic arthritis. Current Opinion in Rheumatology 15(3): 205–212.

    Article  PubMed  CAS  Google Scholar 

  29. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356: 385–390.

    Article  PubMed  CAS  Google Scholar 

  30. Clegg DO, Reda DJ, Weisman MH, et al. (1996) Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39: 2013–2020.

    Article  PubMed  CAS  Google Scholar 

  31. Fries JF, Spitz PW, Young DY (1982) The dimensions of health outcomes: the health assessment questionnaire, disability and pain scale. J Rheumatol 9: 789–793.

    PubMed  CAS  Google Scholar 

  32. Fredriksson T, Pettersson U (1978) Severe psoriasis—oral therapy with a new retinoid. Dermatologica 157: 238–244.

    Article  PubMed  CAS  Google Scholar 

  33. Mease PJ, Goffe BS, Metz J, et al. (2001) Enbrel® (etanercept) in patients with psoriatic arthritis and psoriasis. Ann Rheum Dis 60(Suppl 1): 146.

    Google Scholar 

  34. Mease P, Kivitz A, Burch F, et al. (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50: 2264–2272.

    Article  PubMed  CAS  Google Scholar 

  35. Mease P, Ganguly L, Wanke E, et al. (2004) How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome meausres in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 63(Suppl 1): 391.

    Google Scholar 

  36. Kosinski M, Keller SD, Ware JE Jr, Hatoum HT, Kong SX (1999) The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: relative validity of scales in relation to clinical measures of arthritis severity. Med Care 37(Suppl 5): MS23–39.

    Article  PubMed  CAS  Google Scholar 

  37. Bukhari M, Wiles NJ, Lunt M, et al. (2003) Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum 48: 21–34.

    Article  Google Scholar 

  38. Strand V, Sharp JT (2003) Radiographic data from recent randomized controlled trials in rheumatoid arthritis. Arthritis Rheum 48: 21–34.

    Article  PubMed  Google Scholar 

  39. Emery P (2002) Evidence supporting the benefit of early intervention in rheumatoid arthritis. J Rheumatol 66: 3–8.

    Google Scholar 

  40. Landewé R (2003) The benefits of early treatment in rheumatoid arthritis: confounding by indication, and the issue of timing. Arthritis Rheum 48: 1–5.

    Article  PubMed  Google Scholar 

  41. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G, Salonen D (1998) Radiological assessment in psoriatic arthritis. Br J Rheumatol 37: 760–765.

    Article  PubMed  CAS  Google Scholar 

  42. Ory P, Sharp J, Salonen, D, et al. (2002) Etanercept (Enbrel) inhibits radiographic progression in patients with psoriatic arthritis. Arthritis Rheum 46(Suppl 9): S196.

    Google Scholar 

  43. Sharp JT, Young DY, Bluhm GB, et al. (1985) How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 28: 1326–1335.

    Article  PubMed  CAS  Google Scholar 

  44. FDA Briefing Document for the March 4, 2003 meeting of the Arthritis Advisory Committee: Update on the TNF-Blocking Agents. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930B1_01_B-TNF.Briefing.pdf. Accessed October 31, 2003. 2003.

    Google Scholar 

  45. Antoni C, Dechant C, Hanns-Martin Lorez PD, et al. (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imagine measurements of reduction of inflammation. Arthritis Rheum 47(5): 506–512.

    Article  PubMed  CAS  Google Scholar 

  46. Van den Bosch F, Kruithof E, Baeten D, et al. (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 46(3): 755–765.

    Article  CAS  Google Scholar 

  47. Kruithof E, Van den Bosch F, Baeten D, et al. (2002) Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 61(3): 207–212.

    Article  PubMed  CAS  Google Scholar 

  48. Antoni CE, Kavanaugh A, Kirkham B, et al. (2002) The infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arth Rheum 46(Suppl 9): S381.

    Google Scholar 

  49. Antoni C, Kavanaugh A, Kirkham B, et al. (2005) The infliximab multinational psoriatic arhtritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arthritis Rheum (in press), (IMPACT)

    Google Scholar 

  50. Antoni CE, Kavanaugh A, Kirkham B, et al. (2003) The one year results of the infliximab multinational psoriatic arthritis controlled trial (IMPACT): substantial efficacy on synovitis and psoriatic lesions with or without concomitant DMARD therapy. Arth Rheum 48(Suppl 9): S265.

    Google Scholar 

  51. Antoni C, Kavanaugh A, Gladman DD, et al. (2004) The Infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Arthritis Rheum 50(Suppl 9): S450.

    Google Scholar 

  52. Kavanaugh A, Krueger G, De Vlam K, et al. (2004) Infliximab significantly improves joint and skin involvement in psoriatic arthritis to a substantial extent and irrespective of baseline joint involvement or MTX use: analysis of clinical response from the IMPACT 2 trial. Arthritis Rheum 50(Suppl 9): S617.

    Google Scholar 

  53. Mease P, Kavanaugh A, Krueger G, et al. (2004) Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from the IMPACT 2 trial. Arthritis Rheum 50(Suppl 9): S616.

    Google Scholar 

  54. Weinblatt ME, Keystone EC, Furst DE, et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1): 35–45.

    Article  PubMed  CAS  Google Scholar 

  55. van de Putte LB, Atkins C, Malaise M, Sany J, et al. (2003) Monotherapy in the Treatment of Patients with Severely Active Rheumatoid Arthritis. Arthritis Rheum 46(suppl 9): S205.

    Google Scholar 

  56. Furst DE, Schiff MH, Fleischmann RM, et al. (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 30(12): 2563–2571.

    PubMed  CAS  Google Scholar 

  57. Keystone E, Haraoui B. (2004) Adalimumab therapy in rheumatoid arthritis. Rheum Dis Clin North Am 30(2): 349–364.

    Article  PubMed  Google Scholar 

  58. Ritchlin C, Anandarajaha A, Totterman S, et al. (2004) Preliminary data from a study of adalimumab in the treatment of psoriatic arthritis. Ann Rheum Dis 63(Suppl 1): 403.

    Google Scholar 

  59. Mease P, Gladman DD, Ritchlin C, et al. (2004) Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum 50: 4097.

    Article  CAS  Google Scholar 

  60. Nikas SN, Drosos AA (2003) Onercept. Serono. Curr Opin Investig Drugs 4(11): 1369–1376.

    PubMed  CAS  Google Scholar 

  61. Mease P (2004) TNFalpha therapy in psoriatic arthritis and psoriasis. Ann Rheum Dis 63(7): 755–758.

    Article  PubMed  CAS  Google Scholar 

  62. Tak P-P, Kraan MC, Goedkoop AY, et al. (2003) Early effects of infliximab therapy on inflammatory cells in lesional epidermis and synovial tissue if patients with psoriatic arthritis [abstract]. Arthritis Rheum 47(Suppl 9): Abstract 339.

    Google Scholar 

  63. Tak P-P, Kraan MC, Goedkoop AY, et al. (2003) Infliximab reduces the expression of adhesion molecules in skin and synovial tissue of patients with psoriatic arthritis [abstract]. Arthritis Rheum 47(Suppl 9): Abstract 605.

    Google Scholar 

  64. Veale DJ, Markham T, Fearon U, et al. (2003) Anti-TNF alpha therapy in psoriasis and psoriatic arthritis: clinical and angiogenic responses [abstract]. Arthritis Rheum 47(Suppl 9): Abstract 341.

    Google Scholar 

  65. Canete JD, Sanmarti R, Marsal S, et al. (2003) Antiangiogenic effects of infliximab in synovial tissue in psoriatic arthritis [abstract]. Arthritis Rheum 47(Suppl 1): Abstract 345.

    Google Scholar 

  66. Kruithof E, Baeten D, Van den Bosch F, et al. (2003) Down-regulation of synovial inflammation by TNF alpha blockade with infliximab in spondyloarthropathy: a histopathological study in 20 patients [abstract]. Ann Rheum Dis 62(Suppl 1): Abstract AB0370.

    Google Scholar 

  67. Devos SA, Van Den BN, De Vos M, Naeyaert JM (2003) Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 206(4): 388–390.

    Article  PubMed  CAS  Google Scholar 

  68. Cheifetz A, Smedley M, Martin S, et al. (2003) The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98(6): 1315–1324.

    Article  PubMed  CAS  Google Scholar 

  69. Remicade® (infliximab) prescribing information. Malvern, Pa: Centocor, Inc, 2003.

    Google Scholar 

  70. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46(9): 2287–2293.

    Article  PubMed  Google Scholar 

  71. Garcia I, Miyazaki Y, Araki K, et al. (1995) Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol 25(8): 2401–2407.

    Article  PubMed  CAS  Google Scholar 

  72. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93–129.

    Article  PubMed  CAS  Google Scholar 

  73. Mohan VP, Scanga CA, Yu K, et al. (2001) Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 69(3): 1847–1855.

    Article  PubMed  CAS  Google Scholar 

  74. Ruderman EM, Markenson JA. (2003) Granulomatous infections and tumor necrosis factor antagonist therapies: update through June 2002. Arth Rheum 48(Suppl 9): S241.

    Google Scholar 

  75. Keane J, Gershon S, Wise RP, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15): 1098–1104.

    Article  PubMed  CAS  Google Scholar 

  76. Furst DE, Breedveld FC, Kalden JR, et al. (2004). Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 63Suppl 2: ii2–ii12.

    Article  PubMed  CAS  Google Scholar 

  77. Beauparlant P, Papp K, Haraoui B (1999). The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29(3): 148–158.

    Article  PubMed  CAS  Google Scholar 

  78. Cush JJ, Kavanaugh AF. FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis. Part I: The risk of lymphoma with rheumatoid arthritis (RA) and TNF inhibitors. Available at: http://www.rheumatology.org/research/hotline/0303TNFL.htm.Accessed on October 24, 2003-2003.

    Google Scholar 

  79. Mohan N, Edwards ET, Cupps TR, et al. (2001) Demyelination occurring during anti-tumor necrosis factor therapy for inflammatory arthritides. Arthritis Rheum 44(12): 2862–2869.

    Article  PubMed  CAS  Google Scholar 

  80. Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 44(9): 1977–1983.

    Article  PubMed  CAS  Google Scholar 

  81. Enbrel® (Etanercept) prescribing information. Thousand Oaks, Calif: Immunex Corporation, 2003.

    Google Scholar 

  82. HumiraTM (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories, 2003.

    Google Scholar 

  83. Kavanaugh A, Keenan G, DeWoody K, et al. (2001) Long-term follow-up of patients treated with remicade (infliximab) in clinical trials. Arthritis Rheum 44: S81.

    Article  Google Scholar 

  84. Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359(9306): 579–580.

    Article  PubMed  CAS  Google Scholar 

  85. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB (2003) A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 9(3): 176–178.

    Article  PubMed  Google Scholar 

  86. Ali Y, Shah S (2002) Infliximab-induced systemic lupus erythematosus. Ann Intern Med 137(7): 625–626.

    PubMed  Google Scholar 

  87. Debandt M, Vittecoq O, Descamps V, Le L, X, Meyer O (2003) Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 22(1): 56–61.

    Article  PubMed  CAS  Google Scholar 

  88. Baert F, Noman M, Vermeire S, et al. (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348: 601–608.

    Article  PubMed  CAS  Google Scholar 

  89. Mann DL, McMurray JJ, Packer M, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109: 1594–602.

    Article  PubMed  CAS  Google Scholar 

  90. Anker SD, Coats AJ (2002) How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86(2–3): 123–130.

    Article  PubMed  Google Scholar 

  91. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107(25): 3133–3140.

    Article  PubMed  CAS  Google Scholar 

  92. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138(10): 807–811.

    PubMed  Google Scholar 

  93. Schiff M, Mease PJ, Weinblatt M, et al. (2000) Randomized controlled trial of 25 Mg vs. 50 Mg Enbrel (Etanercept) twice weekly in rheumatoid arthritis (RA). Arth Rheum 43(Suppl 9): S391.

    Google Scholar 

  94. Hansen KE, Cush JJ, Patel S, Genovese MC, Schiff M (2002) The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. Arthritis Rheum 46:9 (Suppl): S538–A1439.

    Google Scholar 

  95. Haraoui PB, Keystone EC, Thorne JC, et al. (2003) The Canadian biologic observational switchover survey (BOSS): Switching from infliximab to etanercept leads to successful treatment of rheumatoid arthritis. Ann Rheum Dis. 62(Suppl 1): Abstract 226.

    Google Scholar 

  96. Bombardieri S, Tzioufas AG, McKenna F, et al. (2004) Efficacy evaluation of adalimumab (Humira) in patients with single and multiple prior biologics in the ReAct trial. Arthritis Rheum 50(Suppl 9): S187.

    Google Scholar 

  97. Genovese MC, Cohen S, Moreland L, et al. (2003) A randomized double-blind controlled study evaluating the safety and efficacy of etanercept vs etanercept plus ankinra in patients with rheumatoid arthritis. Ann Rheum Dis 62(Suppl 1): 66.

    Google Scholar 

References

  1. Bulbul R, Williams WV, Schumacher HR Jr (1995) Psoriatic arthritis. Diverse and sometimes highly destructive. Postgrad Med 97: 97–96, 103–106, 108

    PubMed  CAS  Google Scholar 

  2. Mease P (2003) Psoriatic arthritis/psoriasis. In: Smolen J, Lipsky P (eds) Targeted therapies in rheumatology. Martin Dunitz, London, pp 525–548

    Google Scholar 

  3. Pipitone N, Kingsley GH, Manzo A, et al. (2003) Current concept and new developments in the treatment of psoriatic arthritis. Rheumatology 42: 1138–1148

    Article  PubMed  CAS  Google Scholar 

  4. Antoni C, Kavanaugh A, Kirkham B, et al. (2003) The one-year results of the infliximab multinational psoriatic arthritis controlled trial. Arthritis Rheum 48: S604

    Google Scholar 

  5. Braun J, Sieper J (2000) Anti-TNF alpha: a new dimension in the pharmacotherapy of the spondyloarthropathies? Ann Rheum Dis 59: 404–407

    Article  PubMed  CAS  Google Scholar 

  6. Braun J, Sieper J (2003) Role of novel biological therapies in psoriatic arthritis. Biodrugs 17: 187–199

    Article  PubMed  CAS  Google Scholar 

  7. Mease PJ, Goffe BS, Metz J, et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356: 385–390

    Article  PubMed  CAS  Google Scholar 

  8. Panayi G (1994) Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol 8: 419–427

    Article  PubMed  CAS  Google Scholar 

  9. Utset TO, Auger JA, Peace D, et al. (2002) Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 29: 1907–1913

    PubMed  CAS  Google Scholar 

  10. Costello PJ, Winchester RJ, Curran SA, et al. (2001) Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions that appear antigen driven. J Immunol 166: 2878–2886

    PubMed  CAS  Google Scholar 

  11. Laloux L, Voisin MC, Allain J, et al. (2001) Immnohistological study of enthesis in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 60: 316–321

    Article  PubMed  CAS  Google Scholar 

  12. Tassiulas I, Duncan SR, Centola M, et al. (1999) Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol 60: 479–491

    Article  PubMed  CAS  Google Scholar 

  13. Ritchlin C, Haas-Smith SA, Hicks D, et al. (1998) Patterns of cytokine production in psoriatic synovium. J Rheumatol 25: 1544–1552

    PubMed  CAS  Google Scholar 

  14. Partsch G, Steiner G, Leeb BF, et al. (1997) Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24: 518–523

    PubMed  CAS  Google Scholar 

  15. Giustizieri ML, Mascia F, Frezzolini A, et al. (2001) Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-driven cytokines. J Allergy Clin Immunol 107: 871–877

    Article  PubMed  CAS  Google Scholar 

  16. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907–916

    Article  PubMed  CAS  Google Scholar 

  17. Duan H, Koga T, Kohda F, et al. (2001) Interleukin-8-positive neutrophils in psoriasis. J Dermatol Sci 26: 119–124

    Article  PubMed  CAS  Google Scholar 

  18. Gottlieb AB (2001) Psoriasis: immunopathology and immuno-modulation. Dermatol Clin 19: 649–657

    Article  PubMed  CAS  Google Scholar 

  19. Black RA (2002) Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34: 1–5

    Article  PubMed  CAS  Google Scholar 

  20. Bresnihan B, Cunnane G (1998) Interleukin-1 receptor antagonist. Rheum Dis Clin North Am 24: 615–628

    Article  PubMed  CAS  Google Scholar 

  21. Dinarello CA (1998) Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci 856: 1–11

    Article  PubMed  CAS  Google Scholar 

  22. Gabay C (2003) IL-1 trap. Regeneron/Novartis. Curr Opin Investig Drugs 4: 593–597

    PubMed  CAS  Google Scholar 

  23. Krueger J, Ray A, Tamm I, et al. (1991) Expression and function of interleukin-6 in epithelial cells. J Cell Biochem 45: 327–334

    Article  PubMed  CAS  Google Scholar 

  24. Nurieva RI, Treuting P, Duong J, et al. (2003) Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest 111: 701–706

    Article  PubMed  CAS  Google Scholar 

  25. Plater-Zyberk C, Joosten LA, Helsen MM, et al. (2001) Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108: 1825–1832

    Article  PubMed  CAS  Google Scholar 

  26. Barker JN, Jones ML, Mitra RS, et al. (1991) Modulation of keratinocyte-derived interleukin-8 which is chemotactic for neutrophils and T lymphocytes. Am J Pathol 139: 869–876

    PubMed  CAS  Google Scholar 

  27. Singri P, West DP, Gordon KB (2002) Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 138: 657–663

    Article  PubMed  CAS  Google Scholar 

  28. Asadullah K, Sterry W, Stephanek K, et al. (1998) IL-10 is a key cytokine in psoriasis. J Clin Invest 101: 783–794

    Article  PubMed  CAS  Google Scholar 

  29. Reich K, Garbe C, Blaschke V, et al. (2001) Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. J Invest Dermatol 116: 319–329

    Article  PubMed  CAS  Google Scholar 

  30. Asadullah K, Friedrich M, Hanneken S, et al. (2001) Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histologic, immunohistologic, and molecular biology findings. J Invest Dermatol 116: 721–727

    Article  PubMed  CAS  Google Scholar 

  31. McInnes IB, Illei GG, Danning CL, et al. (2001) IL-10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 167: 4075–4082

    PubMed  CAS  Google Scholar 

  32. Leng SX, Elias JA (1997) Interleukin-11 inhibits macrophage interleukin-12 production. J Immunol 159: 2161–2168

    PubMed  CAS  Google Scholar 

  33. Trepicchio WL, Bozza M, Pedneault G, et al. (1996) Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 157: 3627–3634

    PubMed  CAS  Google Scholar 

  34. Yawalkar N, Karlen S, Hunger R, et al. (1998) Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 111: 1053–1057

    Article  PubMed  CAS  Google Scholar 

  35. Trepicchio WL, Ozawa M, Walters IB, et al. (1999) Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 104: 1527–1537

    Article  PubMed  CAS  Google Scholar 

  36. Krueger JG, Walters IB, Miyazawa M, et al. (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43: 448–458

    Article  PubMed  CAS  Google Scholar 

  37. Weinberg JM (2003) An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 25: 2487–2505

    Article  PubMed  CAS  Google Scholar 

  38. Weinberg JM, Tutrone WD (2003) Biologic therapy for psoriasis: the T cell-targeted therapies — Efalizumab and Alefacept. Cutis 71: 41–45

    PubMed  Google Scholar 

  39. Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345: 248–255

    Article  PubMed  CAS  Google Scholar 

  40. Kraan MC, van Kuijk AWR, Dinant HJ, et al. (2002) Alefacept treatment in psoriatic arthritis. Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 46: 2776–2784

    Article  PubMed  CAS  Google Scholar 

  41. Lebwohl M, Tyring SK, Hamilton TK, et al. (2003) A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349: 2004–2013

    Article  PubMed  CAS  Google Scholar 

  42. Gottlieb AB, Krueger JG, Wittkowski K, et al. (2002) Psoriasis as a model for T cell mediated disease: immunobiologic and clinical effects of treatment of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 138: 591–600

    Article  PubMed  CAS  Google Scholar 

  43. Abrams JR, Kelley SL, Hayes E, et al. (2000) Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 192: 681–693

    Article  PubMed  CAS  Google Scholar 

  44. Nakahara H, Song J, Sugimoto M, et al. (2003) Antiinterleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48: 1521–1529

    Article  PubMed  CAS  Google Scholar 

  45. Fierlbeck G, Rassner G (1990) Treatment of psoriasis and psoriatic arthritis with interferon gamma. J Invest Dermatol 95(Suppl 6)138S–141S

    Article  PubMed  CAS  Google Scholar 

  46. O’Connell PG, et al. (1992) Arthritis in patients with psoriasis treated with gamma-interferon. J Rheumatol 19: 80–82

    PubMed  CAS  Google Scholar 

Download references

Editor information

Editors and Affiliations

  1. Division of Dermatology, Loyola University, Stritch School of Medicine, 2160 S. First Ave., Building 112, Room 342, Maywood, IL, 60153, USA

    Kenneth B. Gordon MD

  2. Division of Rheumatology, Northwestern University, Feinberg School of Medicine, 675 N. St. Clair St., Chicago, IL, 60611, USA

    Eric M. Ruderman MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

(2005). B Psoriatic Arthritis. In: Gordon, K.B., Ruderman, E.M. (eds) Psoriasis and Psoriatic Arthritis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27190-2_19

Download citation

  • DOI: https://doi.org/10.1007/3-540-27190-2_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21280-5

  • Online ISBN: 978-3-540-27190-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation